UBS Maintains Buy on Nurix Therapeutics, Raises Price Target to $31

Benzinga Newsdesk www.benzinga.com Positive 87.8%

Neg 0% Neu 0% Pos 87.8%

UBS analyst David Dai maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $23 to $31.